word count: 165 words 21 Main text word count: 5,097 words 22 Abstract 23 Encephalomyocarditis virus (EMCV) is a picornavirus that produces lytic 24 infections in murine and human cells. Employing a genome-wide CRISPR-Cas9 25 knockout screen to find host factors required for EMCV infection, we identified a role for 26 ADAM9 in EMCV infection. CRISPR-mediated deletion of ADAM9 in multiple human cell 27 lines rendered the cells highly resistant to EMCV infection and cell death. Primary 28 fibroblasts from ADAM9 KO mice were also strongly resistant to EMCV infection and cell 29 death. In contrast, ADAM9 KO and WT cells were equally susceptible to infection with 30 other viruses, including the picornavirus Coxsackie virus B. ADAM9 KO cells failed to 31 produce viral progeny when incubated with EMCV. However, bypassing EMCV entry into 32 cells through delivery of viral RNA directly to the cytosol yielded infectious EMCV virions 33 from ADAM9 KO cells, suggesting that ADAM9 is not required for EMCV replication 34 post-entry. These findings establish that ADAM9 is required for the early stage of EMCV 35 infection, likely for virus entry or viral genome delivery to the cytosol. 36 Importance 37 Viral myocarditis is a leading cause of death in the U.S., contributing to 38 numerous unexplained deaths in people ≤ 35 years old. Enteroviruses contribute to 39 many cases of human myocarditis. Encephalomyocarditis virus (EMCV) infection causes 40 viral myocarditis in rodent models but its receptor requirements have not been fully 41 identified. CRISPR-Cas9 screens can identify host dependency factors essential for 42 EMCV infection and enhance our understanding of key events that follow viral infection, 43 potentially leading to new strategies for preventing viral myocarditis. Using a CRISPR-44 Cas9 screen, we identified A Disintegrin and Metalloproteinase 9 Domain (ADAM9) as a 45 major factor required for the early stages of EMCV infection in both human and murine 46 infection. 47 Results 90
48

Introduction 49
Encephalomyocarditis virus (EMCV) is a non-enveloped, single-stranded RNA 50 (ssRNA) virus in the Cardiovirus genus of the Picornavirus family and is known to cause 51 myocarditis, diabetes, and neurologic and reproductive disorders in rodents and non-52 human primates (1). The virus was first isolated in 1944 from a gibbon that died 53 suddenly from pulmonary edema and myocarditis (2) and later from diseased pigs (3). 54
Since its discovery, EMCV has been isolated globally in an extensive range of animal 55 species (4-7). Rodents, specifically rats, are believed to be the natural reservoir hosts of 56 EMCV, while infection of other animal species may result from occasional cross-species 57 transmission by ingestion of contaminated food, water, or infected carcasses (8) (9) (10) (11) . 58 EMCV has also emerged as a pathogen capable of causing large zoonotic pandemics 59 and decimating domestic animal populations, making it an important veterinary pathogen. 60
While human infections are rare, EMCV can cause symptomatic disease in humans, 61 manifesting as a mild, non-specific febrile illness (12-15). Infection is more prevalent 62 among humans with occupational exposure to animals, particularly hunters (16-18), 63 suggesting a strong zoonotic potential for EMCV. While serious human EMCV infections 64 are generally rare, EMCV rapidly kills human cells such as HeLa cells as well as primary 65 human cells in culture (19, 20) . 66 EMCV is a well-accepted and widely used model for studying mechanisms of 67 virus-mediated immune suppression, viral myocarditis, and insulin-dependent diabetes 68 (21-25). However, little is known about the receptor requirements of EMCV. The virus 69 receptor on host cells is often a key factor in influencing viral tropism for particular 70 tissues, which subsequently results in various disease manifestations of infection. Thus, 71
understanding viral pathogenesis often hinges on identifying the cellular molecules that 72 the virus binds to facilitate cell entry and subsequent infection. Here, we employed a 73 functional genomics approach to identify genes responsible for EMCV-induced lytic 74 infection in both human and murine cells. Using a genome-wide CRISPR-Cas9 screen, 75
we identified ADAM9 as a major EMCV dependency factor (EDF). ADAMs (A Disintegrin 76 And Metalloproteinase domain) are a family of transmembrane metalloproteinases that 77 play important roles in growth factor and cytokine signaling as well as cell-cell signaling, 78 adhesion and extracellular matrix remodeling (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) . In animals, including humans, 79 ADAM9 is ubiquitously expressed in cells of the developing heart, brain, retina, lung, 80 fibroblasts, neutrophils, and platelets (27, 30, (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) . Approximately half of the ADAM 81 family members, including ADAM9, have proteolytic capabilities that modulate the 82 activity of cytokines, chemokines, and growth factors, their associated receptors and cell 83 adhesion molecules (27, 35, 37, 45) . ADAMs have been implicated in a range of human 84 cancers, inflammatory diseases, wound healing, and microbial infections; however, very 85 little is known about the role of ADAMs in viral infection. This study demonstrates that 86 ADAM9 functions as a major EDF involved in the early infection of both human and 87 murine cells. 88 the surviving cells and sgRNA sequences were amplified from integrated proviruses by 114 PCR and deep sequenced as described (53). 115
The screen was performed twice and seven candidates (ADAM9, PA2G4, 116 C1GALT1C1, C1GALT1, SLC39A9, TMEM165, and CELF1) were highly enriched in 117 replicate pools (Fig. 1B) . The top candidate in each pool in replicate experiments was 118 ADAM9, with 6 of 6 sgRNA sequences targeting ADAM9 being significantly enriched 119 (>600 reads) ( Fig. 1B) . ADAM9 sgRNAs were highly enriched in both Library A and 120 Library B pools. Overall, ADAM9 sgRNAs accounted for >70% of the over-represented 121 (>20 reads) sgRNAs recovered from EMCV-resistant cells. The second most abundant 122 candidate was PA2G4, which accounted for >22% of the over-represented sgRNAs. 123 ADAM9 belongs to the ADAM family of type I transmembrane proteins in the zinc-124 dependent metalloproteinase (MP) superfamily and are comprised of 6 different domains 125 each with distinct functions: 1) a pro-domain that maintains the MP domain in latent form, 126
2) MP domain, 3) disintegrin domain, which binds integrins to regulate cell-cell or cell-127 matrix interaction and/or cell migration, 4) a cysteine-rich and epidermal-like growth 128 factor (EGF) domain, thought to promote cell-cell fusion and/or regulate cell adhesion, 5) 129 transmembrane domain, which anchors to the cell surface, and 6) a cytoplasmic tail 130 involved in intracellular signaling (Fig. 1C) . 131
132
ADAM9 is required for EMCV-induced cell death and virus replication in human 133 and murine cells 134
To determine the role of ADAM9 in EMCV infection, we used CRISPR-Cas9 and 135 ADAM9-specific sgRNAs to disrupt ADAM9 expression in HeLa and HEK293T human 136 cell lines. WT and ADAM9-deficient cloned cells were tested for their susceptibility to 137 EMCV-induced cell death by assessing cellular ATP levels in a luciferase-based assay 138 as a measure for cell viability. ADAM9 KO clones were resistant to EMCV infection compared to their WT counterparts ( Fig. 2) . WT and ADAM9 KO cells were challenged 140 with EMCV over a range of MOIs and cell viability and EMCV replication were measured 141 after 24 h (Fig. 2) . WT HeLa cells were sensitive to EMCV-induced cell death at MOI ≥ 142 0.1 ( Fig. 2A) . In contrast, ADAM9 KO HeLa cells were protected from EMCV-induced 143 cell death even at MOI = 10. At MOI = 1, ADAM9 KO HeLa cells were > 99% viable 144 while < 1% of WT HeLa cells survived EMCV challenge. We also examined EMCV-145 induced cell death in HEK293T cells ( Fig. 2C) . WT HEK293T cells were very sensitive to 146 EMCV-induced cell death at all MOIs, with ≤ 5% survival of cells at doses as low as MOI 147 = 0.001. In contrast, ADAM9 KO HEK293T cells survived EMCV challenge at doses up 148 to MOI = 10. Thus, loss of ADAM9 expression rendered HEK293T cells >6 logs less 149 sensitive to EMCV-induced cell death compared to WT cells. We confirmed the role of 150 ADAM9 in EMCV infection by measuring virus replication by plaque assays of culture 151 supernatants. Replication of EMCV was markedly reduced in ADAM9 KO compared to 152 WT cells, suggesting that ADAM9 might be required for EMCV binding and/or entry or 153 post-entry transcription of the viral genome ( Fig. 2B,D) . 154
We next asked if ADAM9 was required for EMCV infection of primary murine 155 cells. Primary lung fibroblasts (pLF) from mice with targeted deletion of ADAM9 (43) and 156 their WT C57BL/6J counterparts were challenged with EMCV. WT pLF were susceptible 157 to EMCV-induced cell death ( Fig. 2E ) and produced high titers of EMCV ( Fig. 2F) . In 158 contrast, ADAM9 KO pLF were highly resistant to EMCV killing and were unable to 159 support EMCV replication. At the highest MOI tested, ADAM9 KO pLF demonstrated 160 some limited EMCV replication, but production of infectious EMCV virions was severely 161 attenuated with an approximate 4-log decrease in infectious virion production (plaque-162 forming units or PFU/mL) by ADAM9 KO compared to WT cultures. These results 163 suggested that murine ADAM9, like human ADAM9, plays a major role in EMCV-specific 164 lytic infection of cells. 165
166
The requirement for ADAM9 in EMCV-induced cell death is not strain-specific 167 Previous EMCV studies suggest that different strains of EMCV may bind to 168 different receptors and that some EMCV strains may use multiple pathways (56, 57). In 169 addition, EMCV strains with different tissue tropism have been identified (1). To 170 determine if the requirement for ADAM9 was EMCV strain-specific, we infected WT and 171 ADAM9 KO immortalized mouse lung fibroblasts (iLF) cells with either EMCV (VR129B, 172 ATCC) or with EMCV-M strain (VR-1479, ATCC). ADAM9 KO cells were resistant to 173 both EMCV strains while WT cells were susceptible ( Fig. 3A,B ). We also tested if 174 ADAM9 deficiency had an impact on replication of other RNA and DNA viruses. WT and 175 ADAM9 KO HeLa cells were challenged with Coxsackie virus B3 (CVB3), vesicular 176 stomatitis virus (VSV), influenza A virus (IAV), or herpes simplex virus-1 (HSV-1). WT 177 and ADAM9 knockout cells were equally susceptible to infection with CVB3, VSV, IAV, 178 and HSV-1 ( Fig. 3C ,D,E,F). Cells infected with VSV showed equal yields of infectious 179 VSV from WT and ADAM9 KO pLF ( Fig. 4C ), suggesting that ADAM9 deficiency did not 180 globally impact RNA virus replication. 181
182
ADAM9 is essential for EMCV infection, but is not directly involved in post-entry 183 replication of viral genomes in the cytosol 184
To determine whether ADAM9 is required for virus binding/entry and/or required 185 at a later step in virus replication post-entry, we transfected infectious EMCV viral RNA 186 (vRNA) into iLF using lipofectamine, thus by-passing the requirement for receptor-187 dependent entry events. iLFs were either infected with intact EMCV virions for 1 h at 188 37C, washed to remove residual free virus, and cultured for 18 h at 37 C ( Fig. 4A) or 189 transfected with EMCV vRNA in lipofectamine and incubated at 37 C (Fig. 4B) . iLFs were also infected with VSV, as a positive control, for 1 h at 37 C, washed, and cultured 191 ( Fig. 4C) . After 18 h, culture supernatants were harvested and EMCV, or VSV, 192 replication was determined by quantifying infectious virions in culture supernatants by 193 plaque assay. EMCV infection of WT cells resulted in productive infection of cells (at 194 least 8 logs within 18 h), while infection of ADAM KO cells, resulted in no virus 195 production ( Fig 4A) . When receptor-mediated cell entry is bypassed by transfection of 196 infectious vRNA directly into the cell, EMCV is capable of replicating in both WT and 197 ADAM9 KO cells ( Fig. 4B) . Together, these results demonstrate that ADAM9 is not 198 directly involved in EMCV replication steps post-entry, but rather facilitates EMCV entry 199 and/or genome delivery into the cell where EMCV vRNA genomes are replicated in an 200 ADAM9-independent manner. 201 202
Rescue of ADAM9 in KO cells restores susceptibility to EMCV 203
We next examined if rescue of ADAM9 expression to ADAM9 KO cells restores 204 EMCV susceptibility. ADAM9 KO and WT HeLa and mouse iLF cells, were transduced 205 with retroviral vectors to express murine ADAM9 (mADAM9) or GFP as a control. 206
Transduced cells were selected and cloned by limiting dilution. Expression of ADAM9 207 was confirmed by western blot analysis ( Fig. 5A) . ADAM9 KO cells rescued with intact 208 wild-type (WT) mADAM9 became susceptible to EMCV-induced cell death ( Fig. 5B) , 209 demonstrating that ADAM9 is both necessary and sufficient to confer EMCV 210 susceptibility. 211 ADAM9 is a multi-functional protein and has several domains that participate in a 212 variety of cell processes. ADAM9 controls receptor-mediated signaling via the proteolytic 213 function of its MP domain and signals via its SH3 domains in the cytoplasmic tail. To 214 determine if mutating the MP domain of ADAM9 impacts susceptibility to EMCV, we 215 rescued ADAM9 KO cells with an enzyme-dead mutant ADAM9 containing a Glu to Ala 216 (E>A) substitution in the MP active site (58). The MP mutant ADAM9 restored EMCV 217 susceptibility to KO cells ( Fig. 5B,C) . Thus, EMCV susceptibility in KO cells rescue with 218 (E>A) mutant was indistinguishable from rescue with WT ADAM9 indicating that the 219 active MP domain is not required for EMCV entry into cells. We next asked if the 220 intracellular signaling domain of ADAM9 was necessary to render cells susceptible to 221 EMCV. We replaced the cytosolic domain of ADAM9 with a V5-epitope tag and 222 expressed the cytoplasmic tail deleted (∆CT) mutant in KO cells ( Fig. 5B,C) . EMCV 223 susceptibility was restored with ADAM9-∆CT rescue suggesting that the cytoplasmic tail 224 of ADAM9 does not play a role in EMCV susceptibility. 225
We also challenged WT, ADAM9 KO and rescued KO cells with varying doses of 226 CVB3. As shown in Fig. 5B , we did not observe any differences in susceptibility to CVB3 227 infection in WT, KO and rescued cells, confirming that ADAM9 is specifically required for 228 EMCV infection. In the present study, we employed a genome-wide CRISPR-Cas9 screen to 241 identify EDFs. The screen recovered multiple host factors, including those involved in 242 the post-translational modification of cell surface proteins (C1GALT1C1, C1GALT1, 243 TMEM165), cellular proliferation (PA2G4), the regulation of mRNA processing (CELF1), 244 and the metalloproteinase ADAM9. We focused on ADAM9 because it was the most 245 strongly enriched candidate in the screen and scored with multiple orthologous sgRNAs. 246
Using a diverse panel of CRISPR-engineered ADAM9 KO human cell lines, as well as 247 primary and immortalized murine cell lines from ADAM9 KO mice, we confirmed 248 ADAM9's involvement in EMCV infection and demonstrated that loss of ADAM9 results 249 in a profound block to the early stages of EMCV infection. To our knowledge, this study 250 is the first to define a direct role for ADAM proteins in EMCV infection. 251
Previous studies have suggested different proteins that may be involved in 252 susceptibility to EMCV, but definitive proof (including reconstitution of knockout cells) 253 has not been forthcoming. For example, vascular cell adhesion molecule 1 (VCAM-1), a 254 member of the immunoglobulin superfamily, found on primary vascular endothelial cells 255 has previously been reported as a receptor for EMC-D strain (62). However, cells lacking 256 VCAM-1 have also been shown to be susceptible to EMCV infection via a yet 257 uncharacterized 70 kDa glycoprotein hypothesized to be responsible for mediating virus 258 binding and attachment in these cells (56). Infection of human cardiomyocytes with two 259 different strains of EMCV demonstrated a requirement for sialic acid and heparan sulfate 260 in one EMCV strain but not the other, raising the possibility that different EMCV strains 261 may bind to different polysaccharides in order to initiate infection (57). While different 262 molecules have been implicated as receptors or attachment factors for specific strains of 263 EMCV, the provenance of these strains has been difficult to authenticate, and we have 264 not been able to obtain many of the strains previously reported to have specific receptor 265 or attachment requirements. However, in this study, we were able to confirm that the two 266 ATCC strains of EMCV both use ADAM9 as their major dependency factor. ADAM9 is 267 likely the 70 kDa putative EMCV receptor identified by Jin et al. (56) . Furthermore, we 268 showed that the dependency on ADAM9 for infection is unique to EMCV as infection 269 with other RNA and DNA viruses was not affected by ADAM9 deficiency. Thus, although 270 previous studies have identified certain cell surface molecules as potential EMCV 271 receptors or EDFs, this is the first report of a definitive, widely-expressed cell surface 272 protein utilized by multiple EMCV strains that is critical for EMCV infection. EMCV infection. However, our rescue experiments showed that neither the 289 metalloproteinase activity nor the cytoplasmic tail of ADAM9 is necessary to support lytic 290 EMCV infection. Furthermore, the finding that EMCV infection does not require a 291 catalytically active proteinase domain suggests that ADAM9 may not act as a proteolytic 292 cofactor and further supports a direct virus-receptor interaction between ADAM9 and 293 EMCV or a non-enzymatic protein-protein interaction of ADAM9 with the EMCV receptor 294 that is required to facilitate virus entry. 295
Our data support that ADAM9 is a crucial protein for EMCV infection; specifically, 296 ADAM9 knockout cells from two mammalian species are not infected by two different 297 EMCV strains, reconstitution of ADAM9 permits EMCV infection, and virus replication is 298 unaffected by ADAM9 deficiency when viral RNA is transfected directly into the cytosol. 299 EMCV may directly bind to ADAM9, but we and others (57) In addition to ADAM9, our CRISPR-Cas9 screen in HeLa cells also identified 307 another gene, PA2G4, which is likely also involved in EMCV susceptibility (Fig. 1) . The 308 PA2G4 gene encodes proliferation-associated protein 2G4, also known as ErbB3-309 binding protein 1 (EBP1), which plays a role in cell signal transduction, transcription and 310 translation, and has been shown to suppress growth in certain cancers, including breast 311 and prostate cancers (66-72). How EBP-1 affects EMCV susceptibility and its 312 relationship to ADAM9 is currently under investigation. 313
The discovery of ADAM9 as a surface protein required for EMCV infection has 314 significant implications on our understanding of virus-host interactions and downstream 315 effects of EMCV infection. We are defining ADAM9's precise role in downstream aspects 316 of EMCV infection. Detailed insight into the mechanism of the EMCV-ADAM9 interaction 317 is crucial to understanding viral pathogenesis. Functional studies examining 318 mechanisms of EMCV binding and entry and potential for ADAM9-mediated cell 319 signaling and cytokine production in response to EMCV infection are currently being 320 explored. 321
Materials and Methods 322
GeCKOv2 library screen 323 H1-HeLa cells expressing the GeCKOv2 CRISPR library (Agilent) were plated for full 324 coverage of the library (both pools A and B). These cells were challenged with EMCV at 325 MOI = 10 until < 5% of living cells remained. The cells were washed and re-plated for 326 another challenge of EMCV for confirmation of resistance. gDNA was isolated by 327 expanding the remaining cells and using Qiagen DNeasy Blood and Tissue kit on 2 x 10 6 328 cells. PCR of was performed with lentiGP-1_F and lentiGP-3_R (sequences below) with 329 the product spanning the sgRNA guide sequences. This PCR product was processed 330 and sequenced using the Illumina NextSeq 500. The library screen was performed twice 331 for each pool of the GeCKOv2 library. 332 333
Cell viability assay 334
Cells were plated at 5,000 cells per well in duplicate on a 96-well flat-bottomed plate and 335 incubated overnight at 37 °C. The cells were challenged with virus at the respective MOI 336 for 1 h, washed with PBS; and 150 L of fresh complete media was added to each well. 337
The plates were incubated for 24 h post infection at 37 °C, 10% CO 2 . The media 338 supernatants were collected and 50 L of fresh media and an equal volume of room 339 temperature CellTiter Glo reagent (Promega G7571) were added to each well and mixed 340 for 2 min at 300 rpm. The reaction was allowed to equilibrate for 10 min, then 80 L of 341 the reaction transferred to an opaque 96-well plates and the signal was detected by 342 luminometer. Institutional Animal Care and Use Committee. Lung fibroblasts were isolated from 391 C57BL/6 WT and ADAM9 KO mice that were in a pure C57BL/6 background. Primary 392 lung fibroblasts were generated from 6-10 week old mice according to a protocol 393 adapted from Yamamoto et al. (73) . Euthanized mice were washed with 90% ethanol to 394 reduce contamination. Whole lung lobes were dissected out and place into sterile PBS. 395
Lungs were then submerged in 70% ethanol for 20 seconds, and then placed into 396 digestion media (DMEM with 0.25% trypsin) and cut into small pieces using a sterile 397 scalpel. The lung pieces were then transferred into 10 mL of digestion media and 398 incubated with shaking at 37 °C. After 30 min, 5 mL of cold complete DMEM (DMEM, 399 10% heat-inactivated FBS, 2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL 400 streptomycin, 250 ng/mL amphotericin B) was added, and the cells were centrifuged for 401 5 min at 350 × g at 4 °C. The cell pellet was removed and resuspended in fresh 402 complete DMEM. For each mouse, the lung pieces and cells were resuspended in 50 403 mL of complete DMEM and then plated in a 225 cm 2 tissue culture flask. The cells were 404 incubated for 10 to 15 days with minimal disruption, with fresh media added after 7 d. 405
For the first passage, the cells and lung pieces were detached from the flasks by 406 scraping, and separated into cells and lung pieces with 70 μm cell strainer. The single-407 cell suspension was either passaged one or two times when 90% confluent in complete 408 DMEM, or used immediately for stimulation. Fibroblasts were immortalized with SV40. 
